Reconstituido (en solucin): es menos estable
Results show statistically significant improvements on all analyzed scores
Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials in adults, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%)
Rather than requesting procedural updates alone, FDA required: Independent data integrity investigations Interviews with current and former employees Three-year retrospective review of invalidated OOS results Comprehensive risk assessments Long-term CAPA programs Annual third-party CGMP audits Continuous oversight of microbiology testing for U.S
These findings align with previous reports indicating that downstream pathways, particularly PI3K/AKT and mTOR, are responsive to hepsin downregulation (Fig
eLife 7 , pii: e33710 (2018)